ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to ...

CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

The European Commission (EC) has approved Andembry (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and ...

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...

As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated ...

Chief executive Chris Viehbacher said on Biogen's results call that a plan to extend the use of the subcutaneous injector into the induction phase of treatment could be a "game changer." ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2024 (third quarter ...

BioArctic’s partner Eisai announces update on regulatory review of lecanemab to treat early Alzheimer’s disease in EU: Stockholm Monday, February 3, 2025, 13:00 Hrs [IST] BioA ...